The deal provides a path forward for NextCure with substantial funding from the PIPE, but existing shareholders face heavy dilution. Monitor the proxy statement for exact exchange ratios and shareholder vote on the merger. The CVRs for legacy NextCure assets have uncertain value. Watch for regulatory approvals and Nasdaq listing conditions.
Price Chart
Executive Summary
NextCure (NXTC) announces a reverse merger with private biotech Avere Therapeutics, structured as a two-step merger where Avere shareholders will control the combined entity (renamed Avere Therapeutics, Inc.). Concurrently, Avere is raising at least $150M in a PIPE financing from institutional investors. NextCure's existing shareholders will receive shares in the combined company plus Contingent Value Rights (CVRs) representing the legacy NextCure assets. The deal values Avere at $250M equity value and provides a substantial capital infusion to the combined entity.
Key Financial Metrics
Key Facts
- NextCure to acquire Avere Therapeutics via two-step merger; combined company will be named Avere Therapeutics, Inc.
- Avere valued at $250M equity value; NextCure's Parent Valuation set at $11M minus any cash shortfall
- Concurrent PIPE financing of at least $150M (minimum concurrent investment amount) from institutional investors
- NextCure shareholders to receive shares in combined entity plus CVRs for legacy NextCure assets (transferred to NewCo)
- Existing NextCure management and board will be replaced by Avere designees; Michael Richman resigns as CEO
- NextCure to wind down legacy business; excess cash distributed via pre-closing dividend or CVRs
- Deal expected to close by April 14, 2027, subject to stockholder approval, SEC effectiveness, and Nasdaq listing
- NextCure termination fee: $330,000; Avere termination fee: $2,000,000
Financial Impact
NextCure's $8M market cap is being folded into a combined entity with a $250M+ equity valuation and at least $150M in cash from the PIPE, resulting in extreme dilution for existing NextCure shareholders (estimated ~2-3% pro forma ownership) but a significant premium over the pre-deal market value
Risk Factors
- Deal termination risk if conditions (PIPE minimum, shareholder approval, regulatory) are not met
- Extreme dilution to existing NextCure shareholders (estimated pro forma ownership below 5%)
- Integration risk and potential delays in closing; CVR value for legacy assets is uncertain
- Nasdaq delisting risk if reverse stock split or listing requirements are not satisfied
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (NXTC) — Batch item 1 | 0001104659-26-083327 |
| Document: tm2620428d1_ex10-3.htm | 0001104659-26-083326 |
| Document: tm2620428d1_ex10-6.htm | 0001104659-26-083327 |
| 8-K Filing (NXTC) — Batch item 4 | 0001104659-26-083326 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.22 (−3.95%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.22 (+22.36%) |
Aug 4, 2026 11w ago | 425 | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.22 (+3.88%) |
Jul 14, 2026 14w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.22 (−20.59%) |
Jul 14, 2026 14w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.22 (+20.59%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.22 (+54.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers